Over the past decade, significant advances have been made in the treatment of leukemia through the ongoing development of gene-based targeted therapies. New research provides greater understanding of the optimal use of several BCR-ABL inhibitors for the treatment of acute lymphoblastic leukemia and chronic myeloid leukemia, and how a new gene target functions for several myeloid malignancies.